These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32541319)

  • 1. New drugs in gastrointestinal stromal tumors.
    Martin-Broto J; Moura DS
    Curr Opin Oncol; 2020 Jul; 32(4):314-320. PubMed ID: 32541319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapeutic agents in gastrointestinal stromal tumours.
    Falkenhorst J; Hamacher R; Bauer S
    Curr Opin Oncol; 2019 Jul; 31(4):322-328. PubMed ID: 31033566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
    Serrano C; Bauer S
    Curr Oncol Rep; 2022 Feb; 24(2):151-159. PubMed ID: 35061196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
    Banks E; Grondine M; Bhavsar D; Barry E; Kettle JG; Reddy VP; Brown C; Wang H; Mettetal JT; Collins T; Adeyemi O; Overman R; Lawson D; Harmer AR; Reimer C; Drew L; Packer MJ; Cosulich S; Jones RD; Shao W; Wilson D; Guichard S; Fawell S; Anjum R
    Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32350132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
    Mohammadi M; Gelderblom H
    Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
    [No Abstract]   [Full Text] [Related]  

  • 6. [Advanced GIST: Which treatments in 2022?].
    Mas L; Bachet JB
    Bull Cancer; 2022 Oct; 109(10):1082-1087. PubMed ID: 35934543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging drugs for the treatment of gastrointestinal stromal tumors.
    Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ripretinib: First Approval.
    Dhillon S
    Drugs; 2020 Jul; 80(11):1133-1138. PubMed ID: 32578014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Drug Therapy for Gastrointestinal Stromal Tumour.
    Liu J; Li J; Zhu Y; Jing R; Ding S; Zhang J; Zhao L; Chen Y; Shen J
    Curr Med Chem; 2024; 31(21):3057-3073. PubMed ID: 37151058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
    Keretsu S; Ghosh S; Cho SJ
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.
    Huang WK; Wu CE; Wang SY; Chang CF; Chou WC; Chen JS; Yeh CN
    Curr Treat Options Oncol; 2022 Sep; 23(9):1303-1319. PubMed ID: 35976553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next questions for the medical treatment of gastrointestinal stromal tumor.
    Italiano A
    Curr Opin Oncol; 2022 Jul; 34(4):348-353. PubMed ID: 35730519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
    Janku F; Abdul Razak AR; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Somaiah N; Hu S; Rosen O; Su Y; Ruiz-Soto R; Gordon M; George S
    J Clin Oncol; 2020 Oct; 38(28):3294-3303. PubMed ID: 32804590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New treatments in advanced gastrointestinal stromal tumor.
    Serrano C
    Curr Opin Oncol; 2021 Jul; 33(4):323-328. PubMed ID: 33867479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New drug approvals: Ripretinib for advanced gastrointestinal stromal tumors (GIST) in fourth or later-line therapy].
    Lemaître J; Watson S
    Bull Cancer; 2022 Mar; 109(3):250-252. PubMed ID: 35094842
    [No Abstract]   [Full Text] [Related]  

  • 16. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
    Gebreyohannes YK; Wozniak A; Zhai ME; Wellens J; Cornillie J; Vanleeuw U; Evans E; Gardino AK; Lengauer C; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Cancer Res; 2019 Jan; 25(2):609-618. PubMed ID: 30274985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours.
    Naito Y; Nishida T; Doi T
    Gastric Cancer; 2023 May; 26(3):339-351. PubMed ID: 36913072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.
    Patel SR; Reichardt P
    Cancer; 2021 Jul; 127(13):2187-2195. PubMed ID: 33974733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval.
    Goggin C; Stansfeld A; Mahalingam P; Thway K; Smith MJ; Huang P; Jones RL; Napolitano A
    Future Oncol; 2022 Aug; 18(26):2967-2978. PubMed ID: 35880452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ripretinib (Qinlock) for GIST.
    Med Lett Drugs Ther; 2021 Apr; 63(1621):e56-e57. PubMed ID: 33830971
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.